Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 October 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 190 pages)

 

Export 70 results:
Author Title Type [ Year(Desc)]
Filters: Author is Leufkens, H. G.  [Clear All Filters]
2008
E. Setakis, Leufkens, H. G., and van Staa, T. P., Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
T. P. van Staa, Rietbrock, S., Setakis, E., and Leufkens, H. G., Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?, J Intern Med, vol. 264, pp. 481-92, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
T. P. van Staa, Cooper, C., Barlow, D., and Leufkens, H. G., Individualizing the risks and benefits of postmenopausal hormone therapy, Menopause, vol. 15, pp. 374-81, 2008.
M. J. Willemen, Mantel-Teeuwisse, A. K., Straus, S. M., Leufkens, H. G., and Egberts, A. C., Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs, Obesity (Silver Spring), vol. 16, pp. 2331-5, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., What is the harm-benefit ratio of Cox-2 inhibitors?, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
[Page last reviewed 4 October 2019]